-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Melanoma is a cancer developed from melanin cells and is a rare form of skin cancer.
good for the skin but may also appear in the mouth, intestines or eyes.
most commonly in the legs in female patients, while male patients are most commonly found in the back.
pharmaceutical company OncoSec announced today that the first patient has been treated with the in-tumor DNA plasmid TAVO (tavokinogene telseplasmid) anti-PD-1 checkpoint inhibitor OPDIVO (nivolumab).
phase II trial was designed to assess the effectiveness of TAVO combined OPDIVO as a new complementary therapy for patients with advanced melanoma.
clinical results have been shown when opdivo (nivolumab), an anti-PD1 checkpoint inhibitor, is used as a new complementary therapy, rapid recurrence remains a problem for many patients.
TAVO combined OPDIVO may promote a deep anti-tumor response and completely eliminate tumors before surgery, resulting in long-term clinical improvements for a significant proportion of patients treated.
combination of TAVO with another anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), has been shown to improve the overall remission rate in patients with the checkpoint inhibitor refrectable metastasis melanoma.